Post transplant diabetes mellitus after renal transplantation: The emerging clinical challenge

Yonsei Medical Journal

Volumn 45, Issue 6, 2004, Pages 1059-1064

  Ravindran, Vinod ^a   Baboolal, Keshwar ^a   Moore, Richard ^a  

^a UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIGUANIDE DERIVATIVE; CALCINEURIN; CORTICOSTEROID; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; INSULIN; ORAL ANTIDIABETIC AGENT; RAPAMYCIN; STEROID; SULFONYLUREA; TACROLIMUS;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COUNSELING; DIABETES MELLITUS; DIAGNOSTIC PROCEDURE; DIET THERAPY; DRUG CLEARANCE; GRAFT REJECTION; GRAFT SURVIVAL; HIGH RISK PATIENT; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INSULIN RESISTANCE; KIDNEY TRANSPLANTATION; LACTIC ACIDOSIS; LIFESTYLE; PATHOPHYSIOLOGY; POSTOPERATIVE PERIOD; PREVALENCE; REVIEW; RISK FACTOR; SCREENING TEST;

EID: 12344311112     PISSN: 05135796     EISSN: None     Source Type: Journal    
DOI: 10.3349/ymj.2004.45.6.1059     Document Type: Review

References (43)

1. Kasiske BL, Chakkaraha, Rowal J. Explained and unexplained Ischaemic heart disease risk after renal transplantation. J Am Soc Nephrol 2000;11;1735-43.
2. Chilcott,JB, Whitby SM, Moore R. Clinical impact and health economic consequences of post transplant type II diabetes mellitus. Transplant Proc 2001;33(5A Suppl): 32S-9S.
3. Wolfe RA, Ashby VB, Milford EL, Ojo AO, Ettenger RE, Agodoa LY, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999;341:1725-30.
4. Levey AS. The improving prognosis after kidney transplantation. New strategies to overcome immunologic rejection. Arch Intern Med 1984;144:2382-7.
5. Ojo AO, Hanson JA, Wolfe RA, Leichtman AB, Agodoa LY, Port FK. Long term survival in renal transplant recipients with graft function. Kidney Int 2000;57:307-13.
6. Peterson PK, Anderson RC. Infection in renal transplant recipients. Current approaches to diagnosis, therapy, and prevention. Am J Med, 1986;81(1A):2-10.
7. Kasiske BL. Epidemiology of cardiovascular disease after renal transplantation. Transplantation 2001;72(6 Suppl):S5-8.
8. Cosio FG, Pesavento TE, Osei K, Henry ML, Ferguson RM. Post-transplant diabetes mellitus: increasing incidence in renal allograft recipients transplanted in recent years. Kidney Int 2001;59:732-7.
9. Miles AM, Sumrani N, Horowitz R, Homel P, Maursky V, Markell MS, et al. Diabetes mellitus after renal transplantation: as deleterious as non-transplant-associated diabetes? Transplantation 1998;65:380-4.
10. Fernandez LA, Lehmann R, Luzi L, Battezzati A, Angelico MC, Ricordi C, et al. The effects of maintenance doses of FK506 versus cyclosporin A on glucose and lipid metabolism after orthotopic liver transplantation. Transplantation 1999;68:1532-41.
11. Paolillo JA, Boyle GJ, Law YM, Miller SA, Lawrence K, Wagner K, et al. Posttransplant diabetes mellitus in pediatric thoracic organ recipients receiving tacrolimus-based immunosuppression. Transplantation 2001;71: 252-6.
12. Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes. Diabetologia 2003;46:3-19.
13. Ekstrand AV, Eriksson JG, Gronhagen-Rigka C, Ahonen PJ, Groop LC. Insulin resistance and insulin deficiency in the pathogenesis of posttransplantation diabetes in man. Transplantation 1992;53:563-9.
14. Vesco L, Busson M, Bedrossian J, Bitker MO, Hiesse C, Lang P. Diabetes mellitus after renal transplantation: characteristics, outcome, and risk factors. Transplantation 1996;61:1475-8.
15. Cho YM, Park KS, Jung HS, Jeon HJ, Ahn C, Ha J, et al. High incidence of tacrolimus-associated posttransplantation diabetes in the Korean renal allograft recipients according to American Diabetes Association criteria. Diabetes Care 2003;26:1123-8.
16. Montori VM, Basu A, Erwin PJ, Velosa JA, Gabriel SE, Kudva YC. Posttransplantation diabetes: a systematic review of the literature. Diabetes Care 2002;25:583-92.
17. Reisaeter AV, Hartmann A. Risk factors and incidence of posttransplant diabetes mellitus. Transplant Proc 2001;33(5A Suppl):8S-18S.
18. Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003;3:178-85.
19. Mayer AD, Dmitrewski J, Squifflet JP, Besse T, Grabensee B, Klein B, et al. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group. Transplantation 1997;64:436-43.
20. Pirsch JD, Miller J, Deierhoi MH, Vincenti F, Filo RS. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation 1997;63:977-83.
21. Davidson J, Wilkinson A, Dantal J, Dotta F, Haller H, Hernandez D, et al. New-onset diabetes after transplantation: 2003 International consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003. Transplantation 2003;75(10 Suppl):SS3-24.
22. Midtvedt K, Hartmann A, Hjelmesaeth J, Lund K, Bjerkely BL. Insulin resistance is a common denominator of post-transplant diabetes mellitus and impaired glucose tolerance in renal transplant recipients. Nephrol Dial Transplant 1998;13:427-31.
23. Hjelmesaeth J, Hartmann A, Kofstad J, Stenstrom J, Leivestad T, Egeland T, et al. Glucose intolerance after renal transplantation depends upon prednisolone dose and recipient age. Transplantation 1997;64:979-83.
24. Knol GA. Tacrolimus versus Cyclosporiin for immunosuppression in renal transplantation: meta-analysis of randomised trials. BMJ 1999;24;318;1104-7.
25. Heisel O, Heisel R, Balshaw R, Keown P. New onsel diabetes Mellitus in patients receiving calcineurin inhibitors; a systomatic review and meta analysis. Am J Transplant 2004;4:583-95
26. Sato T, Inagaki A, Uchida K, Ueki T, Goto N, Matsuoka S, et al. Diabetes mellitus after transplant: relationship to pretransplant glucose metabolism and tacrolimus or cyclosporine A-based therapy. Transplantation 2003;76: 1320-6.
27. Nam JH, Mun JI, Kim SI, Kang SW, Choi KH, Park K, et al. beta-Cell dysfunction rather than insulin resistance is the main contributing factor for the development of postrenal transplantation diabetes mellitus. Transplantation 2001;71:1417-23.
28. Bloom RD, Rao V, Weng F, Grossman RA, Cohen D, Mange KC. Association of hepatitis C with posttransplant diabetes in renal transplant patients on tacrolimus. J Am Soc Nephrol 2002;13:1374-80.
29. Alvestrand A, Mujagic M, Wajngot A, Efendic S. Glucose intolerance in uremic patients: the relative contributions of impaired beta-cell function and insulin resistance. Clin Nephrol 1989;31:175-83.
30. Evans DJ, Hoffmann RG, Kalkhoff RK, Kissebah AH. Relationship of body fat topography to insulin sensitivity and metabolic profiles in premenopausal women. Metabolism 1984;33:68-75.
31. Despres JP, Nadeau A, Tremblay A, Ferland M, Moorjani S, Lupien PJ, et al. Role of deep abdominal fat in the association between regional adipose tissue distribution and glucose tolerance in obese women. Diabetes 1989;38:304-9.
32. Dufer M, Krippeit-Drews P, Lembert N, Idahl LA, Drews G. Diabetogenic effect of cyclosporin A is mediated by interference with mitochondrial function of pancreatic B-cells. Mol Pharmacol 2001;60:873-9.
33. Hirano Y, Fujihira S, Ohara K, Katsuki S, Noguchi H. Morphological and functional changes of islets of Langerhans in FK506-treated rats. Transplantation 1992; 53:889-94.
34. Oetjen E, Baun D, Beimesche S, Krause D, Cierny I, Blume R, et al. Inhibition of human insulin gene transcription by the immunosuppressive drugs cyclosporin A and tacrolimus in primary, mature islets of transgenic mice. Mol Pharmacol 2003;63:1289-95.
35. van Duijnhoven EM, Christiaans MH, Boots JM, Nieman FH, Wolffenbuttel BH, van Hooff JP. Glucose metabolism in the first 3 years after renal transplantation in patients receiving tacrolimus versus cyclosporine-based immunosuppression. J Am Soc Nephrol 2002;13:213-20.
36. Cosio FG, Pesavento TE, Kim S, Osei K, Henry M, Ferguson RM. Patient survival after renal transplantation: IV. Impact of post-transplant diabetes. Kidney Int 2002;62:1440-6.
37. Friedman EA, Shyh TP, Beyer MM, Manis T, Butt KM. Posttransplant diabetes in kidney transplant recipients. Am J Nephrol 1985;5:196-202.
38. Kasiske BL, Guijarro C, Massy ZA, Wiederkehr MR, Ma JZ. Cardiovascular disease after renal transplantation. J Am Soc Nephrol 1996;7:158-65.
39. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988;37:1595-607.
40. Hjelmesaeth J, Hartmann A, Midtvedt K, Aakhus S, Stenstrom J, Morkrid L, et al. Metabolic cardiovascular syndrome after renal transplantation. Nephrol Dial Transplant 2001;16:1047-52.
41. Lemieux I, Houde I, Pascot A, Lachance JG, Noel R, Radeau T, et al. Effects of prednisolone withdrawal on the new metabolic triad in cyclosporine-treated kidney transplant patients. Kidney Int 2002;62:1839-47.
42. Moore R, Boucher A, Carter J, Kim SJ, Kiberd B, Loertscher R, et al. Diabetes mellitus in transplantation; 2002 consensus guidelines. Transplant Proc 2003;35: 1265-70.
43. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998;15:539-53.